Mr. Chris Dallin reports

ASEP MEDICAL ANNOUNCES $1 MILLION SECURED LOAN FACILITY

Asep Medical Holdings Inc. has entered into a loan facility agreement dated Oct. 8, 2026, with an arm's-length private lender in respect of a non-revolving term loan facility in the principal amount of $1-million (U.S.). The proceeds of the facility will be used to finance the company's short-term working capital requirements, ordinary-course operating expenses and general corporate purposes.

The facility will be advanced partially or fully no later than five days following written request and will mature 24 months from the execution of the facility, subject to earlier acceleration following the occurrence and continuation of an event of default. The facility will bear interest at a rate of 12 per cent per annum. The company may voluntarily prepay the facility and all accrued interest, in whole or in part any time prior to the maturity date. The facility is secured against a general security over all present and after-acquired personal property of the company, including accounts, equipment, inventory, cash, contractual rights, intellectual property and all proceeds thereof.

No securities of the company will be issued in connection with the facility, and no finder's fee, commission or loan bonus is payable.

The advance of funds under the facility remains subject to the satisfaction or waiver of the conditions precedent contained in the loan agreement and acceptance of the Canadian Securities Exchange to the extent required. Closing of the facility is expected to occur on Friday, Oct. 9, 2026.

About Asep Medical Holdings Inc.

Asep Medical is an investment issuer focused on investing into biotechnology research and development assets and is based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists. Asep holds a significant interest in two private companies -- Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

We seek Safe Harbor.